Talphera

Talphera Liabilities

The The Liabilities of Talphera (TLPH) as of Nov 22, 2026 is 12.68 M USD. In the previous year, The Liabilities was 10.24 M USD — a change of 23.93% (higher).

Liabilities

12.68 MUSD

YoY

23.93%

Last updated:

In 2025, Talphera's total liabilities amounted to 12.68 M USD, a 23.93% difference from the 10.24 M USD total liabilities in the previous year.

The Talphera Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
116.28 M USD
Jan 1, 2019
132.77 M USD
Jan 1, 2020
122.05 M USD
Jan 1, 2021
113.79 M USD
Jan 1, 2022
25.67 M USD
Jan 1, 2023
6.29 M USD
Jan 1, 2024
10.24 M USD
Jan 1, 2025
12.68 M USD
The Talphera Liabilities history
YEARLiabilitiesYoY
12.68 MUSD+23.93%
10.24 MUSD+62.72%
6.29 MUSD-75.50%
25.67 MUSD-77.44%
113.79 MUSD-6.77%
122.05 MUSD-8.08%
132.77 MUSD+14.18%
116.28 MUSD+3.76%
112.06 MUSD+6.39%
105.33 MUSD+11.26%
94.67 MUSD+138.11%
39.76 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Talphera Stock analysis

What does Talphera do? Talphera Inc develops and commercializes therapies for medically supervised settings, focusing on nafamostat-based products. The company's Niyad targets regional anticoagulants for dialysis circuits in acute kidney injury and chronic kidney disease patients. LTX-608 is an intravenous formulation for potential treatment of viral infections, ARDS, DIC, and acute pancreatitis. Pre-filled syringes Fedsyra and PFS-02 are also under development. The firm sells these products to hospitals, dialysis centers, and medical facilities requiring specialized therapies in controlled environments. Niyad is designed for use during continuous renal replacement therapy and hemodialysis procedures, primarily targeting healthcare providers in hospital settings and dialysis centers. LTX-608 aims to address viral and inflammatory conditions, with potential buyers including hospitals treating respiratory and coagulation disorders. The pre-filled syringes Fedsyra and PFS-02 serve as delivery systems for these therapies, appealing to medical institutions needing efficient administration solutions. The company's revenue streams come from the sale of Niyad, LTX-608, Fedsyra, and PFS-02 to healthcare providers. Hospitals and dialysis centers are key buyers for Niyad, while LTX-608 targets hospitals managing viral outbreaks and severe inflammatory conditions. Fedsyra and PFS-02 are sold as complementary products to support the delivery of nafamostat therapies, with demand driven by the need for specialized medical treatments in supervised care settings. Talphera is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Talphera's Liabilities

Talphera's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Talphera's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Talphera's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Talphera's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Talphera’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Talphera stock

The Liabilities of Talphera is 12.68 M USD in 2025.

The Liabilities of Talphera changed from 10.24 M USD to 12.68 M USD, representing a 23.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Talphera since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Talphera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Talphera

All Key Metrics — Talphera